General Anxiety Disorder Treatment Market - Global Industry Analysis

General Anxiety Disorder Treatment Market- By Drug Class (Antidepressants, Benzodiazepines, and Buspirone), By Indication (General Anxiety and Depression), and By Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy): Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends And Forecast, 2022 – 2028

Published Date: 19-Apr-2022 Category: Pharmaceutical Report Format : PDF Pages: 178 Report Code: ZMR-34 Status : Published

The global General Anxiety Disorder Treatment Market accrued earnings worth approximately 11.01 (USD Billion) in 2021 and is predicted to gain revenue of about 14.03 (USD Billion) by 2028, is set to record a CAGR of nearly 2.8% over the period from 2022 to 2028.

Description

General Anxiety Disorder Treatment Market: Industry Prospective

The global General Anxiety Disorder Treatment Market accrued earnings worth approximately 11.01 (USD Billion) in 2021 and is predicted to gain revenue of about 14.03 (USD Billion) by 2028, is set to record a CAGR of nearly 2.8% over the period from 2022 to 2028. The study provides an assessment and analysis of the General Anxiety Disorder Treatment Market on a global & regional level. It offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2021 along with a forecast from 2022 to 2028 based on revenue (USD Billion).

General Anxiety Disorder Treatment Market: Synopsis

General Anxiety Disorder is a mental health ailment producing fear, worry, and a consistent feeling of getting overwhelmed. Apart from this, it features excess, constant, and unrealistic worry about routine activities among individuals. Moreover, the worry can be of health issues, family, and financial matters. According to NCBI, nearly twenty percent of adults suffer from this disorder each year. Reportedly, a general anxiety disorder can have physical as well as emotional effects on a person. An individual suffering from general anxiety disorder possesses unrealistic & exaggerated fears or imaginary fears which are not connected with anything concrete or associated with any such fearsome situation. Moreover, an individual can feel anxious about anything and this is referred to as generalized or general anxiety. It has been found the syndrome or disorder is detected in persons who had suffered from some kind of trauma in childhood, lived through a hard period or suffered losses, and undergo extreme work stress or family problems.

According to NCBI, general anxiety disorder is a common kind of anxiety ailment found both in men and women. Moreover, it is generally found in elderly or middle-aged persons as well as in children. The condition is less common in persons over sixty-five years old. There are different ways of treating this disorder and it includes psychological therapy such as cognitive behavioral treatment, intake of medicines such as anti-depressants, relaxation techniques including meditation, and getting involved in self-help groups.

global General Anxiety Disorder Treatment Market

General Anxiety Disorder Treatment Market: Growth Drivers

The massive growth of the general anxiety disorder treatment industry over the next few years can be attributed to rising in work stress & hectic lifestyle. In addition to this, the rise in the production of medicines for treating general anxiety disorder will open new growth dimensions for the general anxiety disorder treatment market. Furthermore, massive use of psychotherapy and treating patients with psychoactive medicines are few of the effective therapeutic solutions for general anxiety disorder. Moreover, the rise in incidences of general anxiety disorders can be attributed to heredity, stressful event, and brain chemistry. A rise in awareness about mental disorders, early diagnosis of these disorders, and awareness among people about the need for treating them immediately will drive market trends. However, the lack of availability of any specific diagnostics tests for determining general anxiety disorder and its treatment can deter the growth of the general anxiety disorder treatment market. Apart from this, nausea and dry mouth are the side effects associated with the intake of medicines and this can pose a barrier to market expansion.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

General Anxiety Disorder Treatment Market: Regional Landscape

North America General Anxiety Disorder Treatment Market To Witness Exponential Growth By 2028

Regional dominance of North America over forthcoming years can be due to factors such as a rise in cases of general anxiety among the workforce in countries such as the U.S. due to long working hours and hectic & irregular lifestyles. Apart from this, the presence of key players in the sub-continent will contribute sumptuously toward the regional market surge.

General Anxiety Disorder Treatment Market: Competitive Insights

Some of the major players have strongly leveraged the growth of the general anxiety disorder treatment market and will continue to do so even in near future. They are Pfizer, Inc., Merck & Co. Inc., AstraZeneca, GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb, Johnson & Johnson, and H. Lundbeck A/S.

The global General Anxiety Disorder Treatment Market is segmented as follows:

By Drug Class

  • Antidepressants
  • Benzodiazepines
  • Buspirone

By Indication

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table Of Content

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global General Anxiety Disorder market. Zion Research has collected and analyzed key data belong to the global General Anxiety Disorder market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of General Anxiety Disorder across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the General Anxiety Disorder industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the General Anxiety Disorder market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

General anxiety disorder (GAD) is characterized by constant and excessive worrying which is hard to control and lead to considerable impairment or distress. Other psychological symptoms of anxiety include irritability and apprehensiveness, and physical symptoms of anxiety are increased muscular tension and fatigue. Effective treatments for general anxiety disorder are medications and psychotherapy. Psychotherapy includes applied relaxation and cognitive-behavioral therapy among others.

According to anxiety and depression association of America, general anxiety disorder affects 3.1% of the U.S. population or 6.8 million adults, in any given year. U.S. stands for the major regional market for anxiety disorder therapeutics worldwide. Growing geriatric population and rising prevalence of anxiety disorders and depression are some of the key factors to drive the market in the years to come. Currently, U.S. general anxiety disorders market is saturated as a variety of antidepressant drugs are available on prescription for the similar symptom. Presently, general anxiety disorders market is on a decline owing to the weak pipeline of novel drugs, patent expiry of major antidepressants and an increasing number of cheap generic drug variants in the market.

Different therapeutic segments of the general anxiety disorder market include antidepressant, benzodiazepines and other therapeutics. The antidepressant was a major therapeutic segment of general anxiety disorder market and constituted 38.6% share of the total demand in 2014 and is expected to continue its dominance in the market over the forecast period. Numerous kinds of medications employed to treat general anxiety disorder. Antidepressants such as serotonin norepinephrine reuptake inhibitor (SNRI) and selective serotonin reuptake inhibitor (SSRI) classes are the first-line medication treatments. Benzodiazepines (clonazepam, alprazolam, diazepam, and lorazepam) are highly efficient in reducing muscular tension, promoting relaxation and other physical symptoms of anxiety.

General anxiety market is highly competitive in nature owing to the presence of both large and small pharmaceutical companies. Eli Lilly and Company, Sanofi S.A. Forest Laboratories, Inc., Johnson & Johnson H. Lundbeck A/S, Merck & Co., Inc., Pfizer, Inc. are some of the dominant players in the market space.

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Massive growth of general anxiety disorder treatment industry over next few years can be attributed to rise in work stress & hectic lifestyle.

According to Zion market research report, The global General Anxiety Disorder Treatment Market accrued earnings worth approximately 11.01 (USD Billion) in 2021 and is predicted to gain revenue of about 14.03 (USD Billion) by 2028, is set to record a CAGR of nearly 2.8% over the period from 2022 to 2028.

North America will contribute sizably towards the global market revenue over the projected timeline. A massive increase in General Anxiety Disorder Treatment Market size in sub-continent in 2022-2028 can be due to factors such as rise in cases of general anxiety among the workforce in countries such as the U.S. due to long working hours and hectic & irregular lifestyle.     

The key industry participants leveraging business space include Pfizer, Inc., Merck & Co. Inc., AstraZeneca, GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb, Johnson & Johnson, and H. Lundbeck A/S.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed